Dear Editor,

Hyperactivation of mechanistic target of rapamycin (mTOR) signaling is frequently observed in cancer and aging. However, the cellular protective function of mTOR inactivation remains poorly characterized, which may explain the limited therapeutic efficacy of mTOR inhibitors in liver cancer. Accumulating evidence suggests systematic coordination between growth factor-receptor axis and mTOR signaling. Here, we focused on MET, a tyrosine kinase receptor for hepatocyte growth factor (HGF) and a novel regulator of the mTOR machinery.

We observed amino acids (AA)-enhanced phosphorylation of the ribosomal protein S6 kinase 1 (S6K1), a biomarker of mTOR activation, was repressed in MET knockout (KO) HepG2 cells. This phenomenon could be rescued by forced expression of wild-type (WT) MET (Figure S1A). In support of this, the MET inhibitor Capmatinib exhibited near-total inhibition of S6K1 phosphorylation (Figure S1B). Furthermore, we found reintroduction of a kinase-dead (KD) MET mutant was unable to rescue MET KO-caused mTOR inactivation (Figure S1C), while a constitutively active translocated promoter region fused to MET (TPR-MET) mutant enhanced AA-stimulated S6K1 phosphorylation (Figure S1D), suggesting MET mediates AA–mTOR signaling pathway in a phosphorylation-dependent manner.

Interestingly, AA-stimulated mitochondrial oxidative phosphorylation (OXPHOS), including oxidation-reduction reaction (Figures S2A and B) and ATP production (Figures S2C and D), was severely compromised in MET KO cells. Parallel impairments were observed in mice with liver-specific MET deficiency (MetLiver-KO) (Figures S2E and F). We subsequently found HGF greatly enhanced AA-stimulated OXPHOS (Figures S2G and H), and only WT MET could restore functional defects induced by MET KO (Figures S2I and J). Using the vacuolar ATP synthase (V-ATPase) inhibitor Concanamycin A and the mTOR inhibitor Rapamycin, we further demonstrated effects of MET on OXPHOS were dependent on the V-ATPase–mTOR axis (Figure S3A-D).

Intriguingly, we observed the mitochondrial respiratory chain-targeting inhibitor Metformin, or Oligomycin A plus Antimycin A, dramatically inhibited dimerization of MET (Figures S4A and B) and its phosphorylation (Figures S4C and D). Consequently, OXPHOS dysfunction disrupted the MET–ATP6V1A interaction (Figures S4E and F) and AA-stimulated mTOR activation (Figures S4G and H). Both HGF and TPR-MET exacerbated OXPHOS dysfunction-caused cell death, which could be largely rescued by the inhibition of V-ATPase or mTOR (Figures S5A and B). Reconstitution assays in MET KO cells also showed only WT MET exacerbated cell death caused by dysfunctional OXPHOS (Figures S5C and D). Briefly, OXPHOS dysfunction propels a feedback to prevent persistent mTOR activation-caused impairment.

Mechanistically, we found the reactive oxygen species (ROS) scavenger N-acetyl-L-cysteine (NAC) efficiently restored the impairment of mTOR activation in a MET-dependent manner (Figures 1A and B). NAC could also largely rescue MET dimer formation and its phosphorylation from OXPHOS dysfunction (Figures 1C and D). Moreover, WT MET could not rescue mTOR activity suppressed by OXPHOS dysfunction, unless simultaneously administered with NAC; TPR-MET was the most efficient mTOR activator and was not affected by ROS, whereas the MET KD mutant totally lost such function (Figures 1E and F). Furthermore, we observed NAC rescued OXPHOS dysfunction in a MET-dependent manner (Figures 6A and 6B).

Abbreviations: AA, amino acids; HGF, hepatocyte growth factor; KD, kinase-dead; KO, knockout; mTOR, mechanistic target of rapamycin; MET, HGF receptor; NAC, N-acetyl-L-cysteine; OXPHOS, oxidative phosphorylation; Redox, oxidation-reduction reaction; ROS, reactive oxygen species; S6K1, ribosomal protein S6 kinase 1; TPR-MET, translocated promoter region fused to MET; V-ATPase, vacuolar ATP synthase; WT, wild-type
**FIGURE 1** ROS generated from OXPHOS dysfunction suppresses mTOR activation by preventing MET dimerization and phosphorylation. A and B, ROS generated from OXPHOS dysfunction reverses AA-stimulated mTOR activation via MET. WT and MET KO HepG2 (A) or H22 (B) cells (5 × 10⁴) were individually pre-incubated with or without 2 mM metformin for 12 hours or/and 5 mM NAC for 4 hours, then starved for 90 minutes and subsequently stimulated with AA for 45 minutes. Cell lysates were analyzed by immunoblot. C, Mitochondrial ROS disrupts dimerization of MET. HEK-293T cells expressing Flag-MET (1 × 10⁵) were incubated with or without 2 mM metformin for 12 hours or/and 5 mM NAC for 4 hours, then subjected to Native-PAGE and SDS-PAGE, respectively and subsequently analyzed by immunoblot. D, mitochondrial ROS disrupts phosphorylation of MET. HEK-293T cells expressing Flag-MET (1 × 10⁵) were stimulated with HGF then incubated with or without 2 mM Metformin for 12 hours or/and 5 mM NAC for 4 hours. After treatment, cell lysates were analyzed by immunoblot. E, TPR-MET fusion protein abrogates mitochondrial ROS-induced mTOR inactivation. MET KO HepG2 cells (5 × 10⁴) were individually infected with WT MET, TPR-MET, or vesicle control for 48 hours and were then treated with or without 2 mM metformin for 12 hours or/and 5 mM NAC for 4 hours. After treatment, cells were deprived of AA for 90 minutes then stimulated with AA for 45 minutes, and the resultant cell lysates were subjected to immunoblot analysis. F, MET-KD mutant cannot rescue mitochondrial ROS-induced mTOR inactivation. MET KO HepG2 cells (5 × 10⁴) were individually infected with Flag-MET, KD mutant or vector control for 36 hours, and then treated with or without 2 mM metformin for 12 hours or/and 5 mM NAC for 4 hours. After treatment, cells were deprived of AA for 90 minutes then stimulated with AA for 45 minutes, and the resultant cell lysates were subjected to immunoblot analysis.
Notably, overexpression of MET could promote AA-stimulated mTOR activation even in autophagy deficient condition caused by genetic deletion of Atg5 (Figure S7A), or chemical disruption of autophagy flux by Bafilomycin A1 (Figure S7B), which suggested autophagy has no influences on MET-controlled mTOR activation. We further explored the impacts of autophagy on the ROS-driven feedback loop, and results showed even under autophagy deficiency, MET still could facilitate AA-stimulated mTOR activation (Figure S7C) and OXPHOS (Figure S7D); moreover, OXPHOS dysfunction-caused ineffectiveness of MET regulation still could be rescued by NAC. This suggests autophagy is not involved in mitochondrial ROS suspending MET-mTOR-OXPHOS axis.

To investigate the pathological significance of MET-mTOR-ROS loop in tumor growth, we firstly analyzed the impacts of mTOR inhibition and ROS elimination on MET deficient cancer cells in vitro. WT and MET KO HepG2 cells were individually treated with NAC or NAC plus Rapamycin, and results indicated significant synergistic effects of MET and mTOR on the proliferation (Figure S8A), viability (Figure S8B), and colony formation (Figures S8C and D) of cancer cells under ROS clearance. The similar tendencies were also found in Capmatinib-treated MET-driven TPRMET-NIH3T3 cell line (Figure S8E-H).

To determine whether the MET-mTOR-ROS loop is a viable therapeutic target in liver cancer, we constructed multiple mouse models (Figure 2A). In accordance with our in vitro experiments, a combination of Capmatinib and Rapamycin exhibited the strongest inhibitory effects on the SMMC-7721 xenograft model, while NAC reversed proliferative suppression caused by MET inhibition (Figures 2B and C). Similar findings were observed in the Huh-7 xenograft model (Figures 2D and E) and the human TPR-MET-driven NIH3T3 model (Figures 2F and G). Furthermore, Kaplan-Meier curves clearly demonstrated Capmatinib combined with Rapamycin significantly increased, whereas NAC remarkably reduced, the survival rates in both the H22 and Hepa1-6 models (Figures 2H and I).

Additionally, to evaluate the physiological role of the MET-mTOR-ROS loop in liver development, WT and MetLiver-KO mice individually received Rapamycin or/and NAC (Figure S9A). Results suggested Rapamycin significantly decreased, while NAC obviously increased, liver weight in MetLiver-KO mice (Figure S9B). Supporting this, the hepatocytes isolated from the mouse models showed consistent changes in cell viability (Figure S9C). Furthermore, WT and MetLiver-KO mice were used to investigate the impact of MET-mTOR-ROS loop on mice survival (Figure S9D). Results indicated the enormous role of Rapamycin in extending, and conversely NAC in reducing, the overall survival of MetLiver-KO mice (Figure S9E).

In conclusion, we have identified herein that MET as a central component of the mTOR sensing machinery in liver cancer. MET is required for AA-stimulated mTOR activation and mitochondrial OXPHOS in a phosphorylation-dependent manner. Mitochondrial quality in turn dictates MET phosphorylation status and its binding to V-ATPase. Once overloaded, mitochondrial ROS inhibits mTOR activity and OXPHOS to avoid mitochondrial dysfunction-induced tumor cell death, by targeting MET dimerization with disruption of its phosphorylation and interaction with V-ATPase. We provide a schematic model to illustrate the MET-dependent homeostatic maintenance between mTOR activation and OXPHOS (Figure S10A). Through integrating signals of AA and ROS, the MET-mTOR-ROS loop plays a protective checkpoint-like role in liver cancer. We therefore propose this autoregulatory machinery is a promising combinational target for liver cancer therapy. Notably, the indeterminate influence of ROS and the potential side-effects of mTOR inhibition should be further investigated in translation of such therapeutic strategies into clinical practice.

ACKNOWLEDGMENTS
We deeply thank Dr. Bob Weinberg (Whitehead Institute for Biomedical Research) for reagents and Dr. Wei Liu (Zhejiang University), Dr. Canhua Huang (Sichuan University), and Dr. Peter E. Lobie (Tsinghua-Berkeley Shenzhen Institute) for careful reading, critical comments, and constructive suggestions for this manuscript. This study was funded by the grants from the National Natural Science Foundation of China (grant numbers: 31970696 and 81502975 to Xing Huang) and the National Key Research and Development Program (grant numbers: 2019YFC1316000 to Tingbo Liang). The study process, including the study design, collection, analysis, and interpretation of the data and writing of the report, was not influenced by the sponsoring foundation.

CONFLICT OF INTEREST
The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of the research reported.

AUTHOR CONTRIBUTIONS
Xing Huang, Xueli Bai, and Tingbo Liang conceived the project and supervised the study. Xing Huang designed and conducted the major experiments, Gang Zhang helped for metabolic assay, and all authors were involved in data...
FIGURE 2  MTOR inhibition improves, and ROS elimination suppresses, MET-targeted cancer therapy. A, Strategy for evaluating synergistic effects of MET-mTOR inhibition and ROS elimination in MET-targeted cancer therapy. B and C, MTOR inhibition improves, and ROS elimination suppresses the effects of MET inhibition on tumor growth in the SMMC-7721 xenograft model. SMMC-7721 cells (1 × 10⁶) were inoculated subcutaneously into the right flank of nu/nu mice. Once the tumor reached 37.5-42.5 mm², mice received vehicle control PBS (Ctrl, 100 μL), capmatinib (METin, 20 mg/kg), rapamycin (Rapa) (10 mg/kg) or/and NAC (100 mg/kg), respectively. Treatments were administered by subcutaneous multi-point injection adjacent to tumors every 5 days. Tumor growth was regularly reported as tumor size (B) and tumor weight (C). D and E, MTOR inhibition improves, and ROS elimination suppresses the effects of MET inhibition on tumor growth in the Huh-7 xenograft model. Huh-7 cells (1 × 10⁶) were inoculated and treated as described above, and tumor growth was regularly reported. F and G, MTOR inhibition improves, and ROS elimination suppresses the effects of MET inhibition on tumor growth in the TPR-MET-NIH3T3 xenograft model. TPR-MET-driven NIH3T3 cells (5 × 10⁶) were inoculated and treated as described above, and tumor growth was regularly reported. H and I, MTOR inhibition improves, and ROS elimination suppresses the effects of MET inhibition on the survival of the H22 and Hepa1-6 ascite mouse models. H22 (H) and Hepa1-6 (I) cells (5 × 10⁵) were individually inoculated intraperitoneally (i.p.) into nu/nu mice. After 10 days, mice were treated with PBS (Ctrl, 100 μL), METin (30 mg/kg), rapa (15 mg/kg), or/and NAC (150 mg/kg), respectively. Treatments were administered by i.p. injection every 5 days. The mortality was regularly reported with 10 mice per group over 2 months in a Kaplan-Meier plot. Data are presented as the mean ± SD. Statistically significant differences using a two-tailed Student’s t-test are marked as * (P < .05) or ** (P < .01).
analysis and interpretation. Xing Huang and Gang Zhang wrote and revised the manuscript, other authors discussed and commented on the manuscript, and all authors approved the final manuscript version. Xing Huang and Gang Zhang contributed equally to the drafting process. Xing Huang, Xueli Bai, and Tingbo Liang share senior authorship.

ETHICS APPROVAL
The mice experiments performed in this study were approved by Ethics Committee of Southeast University.

AVAILABILITY OF DATA AND MATERIAL
All the data obtained and/or analyzed during the current study are available from the corresponding authors on reasonable request.

CONSENT FOR PUBLICATION
All the authors consent for publication.

**REFERENCES**

1. Sabatini DM. Twenty-five years of mTOR: uncovering the link from nutrients to growth. *Proc Natl Acad Sci U S A*. 2017;114(45):11818-11825.
2. Wolfson RL, Sabatini DM. The dawn of the age of amino acid sensors for the mTORC1 pathway. *Cell Metab*. 2017;26(2):301-309.
3. Zoncu R, Efeyan A, Sabatini DM. mTOR: from growth signal integration to cancer, diabetes and ageing. *Nat Rev Mol Cell Biol*. 2011;12(1):21-35.
4. Lu X, Paliogiannis P, Calvisi DF, Chen X. Role of the mTOR pathway in liver cancer: from molecular genetics to targeted therapies. *Hepatology*. 2020. https://doi:10.1002/hep.31310.
5. Sudhan DR, Guerrero-Zotano A, Won H, et al. Hyperactivation of TORC1 drives resistance to the Pan-HER tyrosine kinase inhibitor neratinib in HER2-mutant cancers. *Cancer Cell*. 2020;37(2):183-199 e5.
6. Hsu PP, Kang SA, Rameseder J, et al. The mTOR-regulated phosphoproteome reveals a mechanism of mTORC1-mediated inhibition of growth factor signaling. *Science*. 2011;332(6035):1317-1322.
7. Huang X, Gan G, Wang X, Xu T, Xie W. The HGF-MET axis coordinates liver cancer metabolism and autophagy for chemotherapeutic resistance. *Autophagy*. 2019;15(7):1258-1279.
8. Yin Y, Hua H, Li M, et al. mTORC2 promotes type I insulin-like growth factor receptor and insulin receptor activation through the tyrosine kinase activity of mTOR. *Cell Res*. 2016;26(1):46-65.
9. Comoglio PM, Trusolino L, Boccaccio C. Known and novel roles of the MET oncoprotein in cancer: a coherent approach to targeted therapy. *Nat Rev Cancer*. 2018;18(6):341-358.
10. Trusolino L, Bertotti A, Comoglio PM. MET signalling: principles and functions in development, organ regeneration and cancer. *Nat Rev Mol Cell Biol*. 2010;11(12):834-848.
11. Huang X, Xu X, Wang X, et al. The AKT-independent MET-V-ATPase-MTOR axis suppresses liver cancer vaccination. *Signal Transduct Target Ther*. 2020;5(1):122.
12. Zou Z, Chang H, Li H, Wang S. Induction of reactive oxygen species: an emerging approach for cancer therapy. *Apoptosis*. 2017;22(11):1321-1335.
13. Rolas L, Makhezer N, Hadjoudj S, et al. Inhibition of mammalian target of rapamycin aggravates the respiratory burst defect of neutrophils from decompensated patients with cirrhosis. *Hepatology*. 2013;57(3):1163-1171.

SUPPORTING INFORMATION
Additional supporting information may be found online in the Supporting Information section at the end of the article.

**How to cite this article:** Huang X, Zhang G, Bai X, Liang T. Combinational therapy targeting the MET-mTOR-ROS loop disrupts mitochondrial autoregulatory machinery of liver cancer. *Clin Transl Med*. 2020;10:1–5. https://doi.org/10.1002/ctm2.237